Metsera, Inc. Poised for Market Outperformance with Innovative Obesity Treatment PlatformWe are initiating coverage of MTSR with an Outperform rating and a PT of $77, based upon DCF valuation. Our investment thesis is that the company’s platform and pipeline of novel obesity peptide-based therapeutics offer key advantages relative to competing assets. We believe that Wall Street underappreciates the company’s monthly injectable GLP-1, monthly injectable amylin, daily oral GLP-1 peptide, and peptide manufacturing peptide scale advantages relative to competitors. We would also highlight that the company is led by highly experienced executives with strong track records, including Chairman Clive Meanwell, CEO Whit Bernard, CFO Chris Visioli, CSO Peter Wijngaard. See management section for details.